Glaucoma
Conditions
Keywords
Pattern electroretinogram, visual field, quality of life, citicoline 500 mg plus homotaurine 50 mg
Brief summary
the general purpose of the study is to evaluate the potential beneficial effects of supplementation of a fixed combination of Citicoline 500 mg plus Homotaurine 50 mg on retinal ganglion cells (RGCs) function in subjects with glaucoma by pattern electroretinogram.
Detailed description
Secondary objectives are to assess effects on visual acuity, visual field changes, Quality of Life perception (NEI VFQ25 questionnaire), and safety (Incidence of adverse events)
Interventions
DIETARY_SUPPLEMENTCiticoline 500 mg plus Homotaurine 50 mg
Citicoline 500 mg plus Homotaurine 50 mg was added to topical therapy
Sponsors
Fondazione IRCCS Policlinico San Matteo di Pavia
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* age between 40 and 75 years; * diagnosis of primary OAG (POAG) from, at least, 3 years; * visual acuity \> 0.7 (7/10) decimals; * refractive error \< 5 D (spheric) and \< 2D (toric); * transparent diopter means (cornea and lens); * controlled IOP (\<18 mmHg, morning value) with beta-blockers and prostaglandin analogues as monotherapy or as associative therapy (fixed or unfixed); * stable IOP\<18 mmHg in the last 2 years; * stable and unchanged topical therapy in the last 6 months; * stable disease in the last 2 years (no more than -1 dB/year at MD of visual field); * at least two reliable visual fields (Humphrey 24-2 Swedish interactive threshold algorithm -SITA- Standard) per year in the last 2 years; * early to moderate visual field defect (MD \<12 dB); * electrophysiological (PERG) parameters alterations similar to glaucomatous pathology; * written consent to participate to study procedures and data utilization in an anonymous form
Exclusion criteria
* ocular hypertension with normal optic nerve and visual field; angle closure glaucoma; * congenital glaucoma; secondary glaucoma; normal tension glaucoma; * history of recurrent uveitis/scleritis/herpes infection; * pregnancy and breastfeeding; * contraindication to Citicoline and/or Homotaurine * contraindication to beta-blockers and prostaglandine analogues * topical therapy with Brimonidine monotherapy or fixed combination (with timolol or brinzolamide) * topical therapy with pilocarpine and aceclidine, monotherapy or fixed combination systemic or topical treatment with another neuroprotective agent in the last 4 months prior to enrollment * systemic therapies affecting patients' performance in visual field examination (sedatives); * glaucomatous scotomas within 10 degree from fixation * any condition limiting the patient's ability to participate in the study; * other ocular causes of visual field and PERG changes, such as cataract, myopic chorioretinopathy, macular diseases, retinal vascular occlusion, diabetic retinopathy; * other systemic causes of visual field and PERG changes such as neurodegenerative disorders (Alzheimer's disease, Parkinson's disease, ALS, MS) or pituitary disorders; * cerebral ischemia in the last 2 years * any change in topical therapy in the 6 months prior to enrollment or during the study period concomitant participation to another clinical trial * any previous filtering and/or retinal surgery; * cataract surgery in the last 6 months; * any previous laser treatment for glaucoma in the last 5 years
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To assess effects of adding the fixed combination of Citicoline 500 mg plus Homotaurine 50 mg (Neuprozin® - NP), one tablet a day, on PERG examination at four months of therapy, compared to standard of care alone, as add-on to standard therapy | 4 months of therapy 2 months of wash out 4 months without adding therapy | changes in amplitude (microVolt) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| to assess effects of one tablet a day of the fixed combination of Citicoline 500 mg plus Homotaurine 50 mg (Neuprozin® - NP) on quality of life | 4 months of therapy 2 months of wash out 4 months without adding therapy | changes in the total mean score and in the subscales of the 25 item National Eye Institute - Visual Functioning Questionnaire (NEI VFQ25) (scores are presented as a number, higher numbers reflect higher QL) |
| To assess effects of one tablet a day of the fixed combination of Citicoline 500 mg plus Homotaurine 50 mg (Neuprozin® - NP) on visual acuity | 4 months of therapy 2 months of wash out 4 months without adding therapy | changes in visual acuity (decimals) |
| to assess effects of one tablet a day of the fixed combination of Citicoline 500 mg plus Homotaurine 50 mg (Neuprozin® - NP) on visual field | 4 months of therapy 2 months of wash out 4 months without adding therapy | changes in mean deviation (deciBell-dB) and in pattern standard deviation (deciBell-dB) of visual field parameters |
Countries
Italy
Outcome results
None listed